Federal contract award
HHSO100200900101C
TAS::75 0140::TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 236210 — Industrial Building Construction |
| PSC | AD61 — CONSTRUCTION - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $1.4B |
| Current contract value | $1.4B |
| Potential contract value / ceiling | $2.3B |
| Start date | Jan 15, 2009 |
| Current end date | Sep 30, 2029 |
| Potential end date | Jan 31, 2034 |
| Latest award activity | Jul 14, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 71 of 71 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 14, 2026 | P00070 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) EXTEND THE PERIOD OF PERFORMANCE FOR OPTION PERIOD 10 FROM JANUARY 31, 2027 TO MAY 31, 2027. 2) THIS EXTENSION WILL BE NO-COST TO THE GOVERNMENT. 3) ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME |
| Jun 10, 2026 | P00069 | $80.8M | THE PURPOSE OF THIS MODIFICATION IS TO: 1) EXERCISE OPTION YEAR 11 (CLIN 0009K). THE PERIOD OF PERFORMANCE FOR THIS OPTION PERIOD IS JUNE 15, 2026 THROUGH JANUARY 31, 2028. 2) AS A RESULT OF THIS CHANGE, THE TOTAL FUNDING VALUE HAS INCREASED T |
| Mar 31, 2026 | P00068 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) AT NO COST TO THE GOVERNMENT, EXTEND THE PERIOD OF PERFORMANCE END-DATE FOR OPTION PERIOD 09 FROM MARCH 31, 2026 TO MAY 31, 2026. 2) ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME AND IN FULL FORCE AND |
| Mar 24, 2026 | P00067 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) UPDATE KEY PERSONNEL TO THE CONTRACT (SEE FOLLOW-ON PAGE). 2) ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME AND IN FULL FORCE AND EFFECT. |
| Feb 23, 2026 | P00066 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) INCREASE THE PRICE OF ANTIGEN STORAGE AND STABILITY FROM $1,959 TO $2,078 PER LOT PER MONTH FOR CLIN 0010 TO ALIGN WITH THE PRICING ESTABLISHED UNDER 75A50122D00004 CLIN 2007B OPTION PERIOD 2. 2) EXTEN |
| Jan 27, 2026 | P00065 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) AT NO COST TO THE GOVERNMENT, EXTEND THE PERIOD OF PERFORMANCE END-DATE FOR OPTION PERIOD 09 FROM JANUARY 31, 2026 TO MARCH 31, 2026 DUE TO DELAYS CAUSED BY THE GOVERNMENT SHUTDOWN. 2) ALL OTHER TERMS |
| Nov 21, 2025 | P00064 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 0017 (PURCHASE AND DELIVERY OF MF59 BULK LOTS TO INCREASE VMI VOLUME) UNTIL SEPTEMBER 30, 2026. 2) ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME AND IN FULL F |
| Oct 14, 2025 | P00063 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) UPDATE KEY PERSONNEL TO THE CONTRACT (SEE FOLLOW-ON PAGE). 2) ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME AND IN FULL FORCE AND EFFECT. |
| Jun 12, 2025 | P00062 | $78.4M | THE PURPOSE OF THIS MODIFICATION IS TO: 1) EXERCISE OPTION YEAR 10 (CLIN 0009J). THE PERIOD OF PERFORMANCE FOR THIS OPTION PERIOD IS JUNE 15, 2025 THROUGH JANUARY 31, 2027. 2) AS A RESULT OF THIS CHANGE, THE TOTAL FUNDING VALUE HAS INCREASED TO |
| Apr 2, 2025 | P00061 | $110.0K | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE LANGUAGE FOR SECTION B.2(D), SECTION C.2 MILESTONES, AND SECTION H.22 LIABILITY PROTECTION. THE TOTAL FUNDING AND CONTRACT VALUE HAS NOT CHANGE. ALL OTHER TERMS AND CONDITIONS ARE IN FULL FORCE |
| Mar 28, 2025 | P00060 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE LANGUAGE FOR SECTION B.2(D), SECTION C.2 MILESTONES, AND SECTION H.22 LIABILITY PROTECTION. THE TOTAL FUNDING AND CONTRACT VALUE HAS NOT CHANGE. ALL OTHER TERMS AND CONDITIONS ARE IN FULL FORCE |
| Dec 9, 2024 | P00059 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR OPTION PERIOD 08 TO 02/28/2025. |
| Sep 24, 2024 | P00058 | $121.4M | THE PURPOSE OF THIS MODIFICATION IS INCORPORATE CHANGES AND ADD FUNDS FOR FULL INVESTMENT INTO THE VMI. |
| Aug 22, 2024 | P00057 | $20.6M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN 022 AND PURCHASE ADDITIONAL LOTS UNDER CLIN 017. |
| Aug 13, 2024 | P00056 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE ADDITIONAL FOUR (4) OPTION LOTS. |
| Jun 13, 2024 | P00055 | $76.1M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION YEAR 09 (0009I). |
| May 31, 2024 | P00054 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO TRANSFER OF FORTY-TWO (42) LOTS FROM HHSO100200900101C TO 75A50122D00004/75A50124F61010. |
| May 14, 2024 | P00053 | $19.4M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE SECTION F.1 & THE PERIOD OF PERFORMANCE FOR LI 0009I THROUGH 0009Q & ADD/EXECUTED CLIN 17. |
| Apr 25, 2024 | P00052 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE CHANGES TO KEY PERSONNEL. |
| Jan 10, 2024 | P00051 | $73.9M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION YEAR 8 (0009H). |
| Sep 11, 2023 | P00050 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE LOT REPLACEMENT. |
| Mar 17, 2023 | P00049 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE KEY PERSONNEL AND LOT REPLACEMENT. |
| Jan 10, 2023 | P00048 | $71.8M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OY7 (0009G) |
| Dec 15, 2022 | P00047 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO FORMALLY TRANSFER TWO INVENTORY BATCHES TO 75A50122D0004 AND 75A50121F33010. |
| Oct 26, 2022 | P00046 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE LOT PRICING. |
| Sep 27, 2022 | P00045 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE DELIVERY DATES FOR LINE ITEM 17. |
| Aug 24, 2022 | P00044 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE KEY PERSONNEL FOR CONTRACT HHSO100200900101C. |
| May 11, 2022 | P00043 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE CONTRACTING OFFICER & AMEND TERMS AND CONDITIONS IN SECTIONS B.4 OWNERSHIP AND USE OF THE FACILITY, C.2 MILESTONE 6, AND F.3 OTHER CONTRACT DELIVERABLES. |
| Jan 10, 2022 | P00042 | $69.7M | EXERCISE OPTION YEAR 6,POP JAN 15, 2022 - JAN 14, 2023, TO PROVIDE A MINIMUM OF 2-4 BULK LOTS OF PRE-PANDEMIC MONOVALENT INFLUENZA VACCINE ADD FUNDING IN THE AMOUNT $69,672,000 |
| Jan 3, 2022 | P00041 | $17.1K | FUND CLIN 0014 IN THE AMOUNT $17,087.00 TO PROVIDE CLINICAL AND REGULATORY SUPPORT FOR STUDIES WHICH INCLUDE MF59 THE BARDA OWNED VMI |
| Dec 20, 2021 | P00040 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO MAKE THE CHANGES TO THE TERMS AND CONDITIONS (SECTION B,C AND F) |
| Oct 27, 2021 | P00039 | $0 | CHANGE CO AND COR AND ADD EXECUTIVE ORDER (E.O.) 14042 FAR DEVIATION CLAUSE-52.223-99 ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS |
| May 24, 2021 | P00038 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE POP FOR OPTION PERIOD 3, DUE TO THE DELAY OF THE SEASONAL INFLUENZA CAMPAIGN PRIORITIZATION BY CBER, EXTENDING THE POP TO JULY 31, 2021. |
| Mar 31, 2021 | P00037 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE POP FOR OPTION PERIOD 3, DUE TO THE DELAY OF THE SEASONAL INFLUENZA CAMPAIGN PRIORITIZATION BY CBER, EXTENDING THE POP TO JULY 31, 2021. |
| Jan 8, 2021 | P00036 | $67.6M | THE PURPOSE OF THIS MODIFICATION IS TO: EXERCISE OPTION V(OY5)PERIOD(JANUARY 15,2021 TO JANUARY 14, 2022) AND A MINIMUM OF 2 (MAX 4) PRE-PANDEMIC $0.00 BULK LOTS OF MONOVALENT INFLUENZA VACCINE |
| Nov 25, 2020 | P00035 | $12.7M | THE PURPOSE OF THIS MODIFICATION IS TO: B. THE PURPOSE OF THIS MODIFICATION IS TO: 1. EXTEND OPTION PERIOD III (A/HUBEI WVS), FROM DECEMBER 31, 2020 TO MARCH 31, 2021 TO ALLOW FOR ADDITIONAL TESTING. 2. ESTABLISH A VENDOR-MANAGED INVENTOR |
| Oct 30, 2020 | P00034 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO 1) SUPPORT VALIDATION OF THE SMALL SCALE FILLING (SSF) FACILITY, 2) EXECUTE AN EXTENSION TO THE BASE PERIOD OF PERFORMANCE THROUGH AUGUST 31, 2021, AND 3)REVISE CONTRACT CLINS. SEE ADDITIONAL PAGES. |
| Aug 28, 2020 | P00033 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1) EXTEND THE PERIOD OF PERFORMANCE (POP) END DATE FOR THE OPTION PERIOD III OF PERFORMANCE, 2) EXTEND THE PERIOD OF PERFORMANCE (POP) END DATE FOR THE OPTION PERIOD IV OF PERFORMANCE, 3) EXTEND THE BASE PERIOD |
| May 28, 2020 | P00032 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Feb 26, 2020 | P00031 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Feb 14, 2020 | P00030 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Jan 15, 2020 | P00029 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Dec 19, 2019 | P00027 | $65.7M | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Dec 19, 2019 | P00028 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| May 30, 2019 | P00026 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES IGF::OT::IGF |
| Jan 4, 2019 | 25 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Dec 21, 2018 | 24 | $63.8M | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Sep 18, 2018 | 23 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Jul 5, 2018 | 22 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| May 17, 2018 | 21 | $0 | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Dec 29, 2017 | 20 | $61.9M | BUILDING DOMESTIC CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITIES |
| Jun 23, 2017 | 19 | $0 | CHANGE CONTRACTING OFFICER'S REPRESENTATIVE |
| Jan 17, 2017 | 18 | $0 | EXTEND BASE CONTRACT PERIOD OF PERFORMANCE UNTIL 12/31/2019 |
| Dec 19, 2016 | 17 | $0 | NOVATION AGREEMENT TO SEQIRUS, INC. |
| Dec 9, 2016 | 16 | $60.1M | EXERCISE OPTION 1 - 01/15/2017 TO 01/14/2018 |
| Apr 30, 2015 | 15 | $0 | CHANGE OF CONTRACTOR KEY PERSONNEL |
| Feb 19, 2015 | 14 | $0 | CHANGE OF HHS OFFICE ADDRESS. |
| Sep 18, 2014 | 13 | $0 | PRE-PANDEMIC ANNUAL LOT DATE EXTENSION. |
| Aug 1, 2014 | 12 | $0 | TO UPDATE CONTRACTOR'S DUNS NUMBER |
| May 20, 2014 | 11 | $0 | TRANSFER EQUIPMENT FROM HHSO100200600012C AND HHSO100200700030C. |
| Mar 31, 2014 | 10 | $0 | CHANGE OF CONTRACTING OFFICER AND CONTRACT SPECIALIST. |
| May 13, 2013 | 9 | $0 | MODIFICATION NO. 9 |
| Feb 4, 2013 | 8 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Oct 1, 2012 | 7 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Sep 25, 2012 | 6 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Sep 24, 2012 | 5 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Aug 8, 2011 | 4 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Jun 28, 2011 | 3 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Oct 13, 2010 | 2 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Jun 7, 2010 | 1 | $0 | COVERS THE CONSTRUCTION OF A CELL-BASED INFLUENZA VACCINE MANUFACTURING FACILITY AND PRODUCTION OF PRE-PANDEMIC INFLUENZA VACCINE. CONTRACT HAS AN EIGHT-YEAR BASE PERIOD AND 17, ONE-YEAR OPTION PERIODS. |
| Jan 13, 2009 | 0 | $486.6M | TAS::75 0140::TAS CONSTRUCTION OF VACCINE MANUFACTURING FACILITY |
Estimated positioning window
Jan 31, 2033 – Jul 31, 2033
Recompete signal: . Rule-based research score; positioning dates are estimates.
35/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 35/100. Available recorded signals: 30 points.
- Contract end 2034-01-31 (2655 days from calculation)
- +5 points
- 0 historical awards in this buyer and category group
- +0 points
- 71 recorded award transactions
- +10 points
- Latest award action: 2026-07-14
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.